This site is intended for healthcare professionals
News

PharmaMar announces the approval of Zepzelca for the treatment of relapsed stage III or metastatic small cell lung cancer.

Read time: 1 mins
Published:6th Oct 2021
PharmaMar has announced that its licensing partner, Jazz Pharmaceuticals plc has received conditional approval from Health Canada for Zepzelca (lurbinectedin) for the treatment of adult patients with relapsed stage III or metastatic small cell lung cancer (SCLC), with disease progression on or after platinum-based chemotherapy.

The conditional approval is subject to confirmation in a Phase III study in 2nd line SCLC, planned to be initiated by the end of 2021.

Lurbinectedin will be available in Canada later this year.

Condition: Small Cell Lung Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights